Background: The aim of this study was to improve the drug loading, encapsulation efficiency, and sustained-release properties of supercritical CO(2)-based drug-loaded polymer carriers via a process of suspension-enhanced dispersion by supercritical CO(2) (SpEDS), which is an advanced version of solution-enhanced dispersion by supercritical CO(2) (SEDS).
Methods: Methotrexate nanoparticles were successfully microencapsulated into poly (L-lactide)-poly(ethylene glycol)-poly(L-lactide) (PLLA-PEG-PLLA) by SpEDS. Methotrexate nanoparticles were first prepared by SEDS, then suspended in PLLA-PEG-PLLA solution, and finally microencapsulated into PLLA-PEG-PLLA via SpEDS, where an "injector" was utilized in the suspension delivery system.
Results: After microencapsulation, the composite methotrexate (MTX)-PLLA-PEG-PLLA microspheres obtained had a mean particle size of 545 nm, drug loading of 13.7%, and an encapsulation efficiency of 39.2%. After an initial burst release, with around 65% of the total methotrexate being released in the first 3 hours, the MTX-PLLA-PEG-PLLA microspheres released methotrexate in a sustained manner, with 85% of the total methotrexate dose released within 23 hours and nearly 100% within 144 hours.
Conclusion: Compared with a parallel study of the coprecipitation process, microencapsulation using SpEDS offered greater potential to manufacture drug-loaded polymer microspheres for a drug delivery system.
Keywords: drug loading; encapsulation efficiency; methotrexate; nanoparticles; poly(L-lactide); supercritical CO2 sustained release.